| Followers | 8 |
| Posts | 2087 |
| Boards Moderated | 0 |
| Alias Born | 07/31/2006 |
Friday, February 28, 2014 7:43:45 PM
NanoViricides Demands Retraction of Baseless, Inaccurate Libelous Article by an Anonymous Short Seller Posted on SeekingAlpha Website
http://finance.yahoo.com/news/nanoviricides-inc-demands-retraction-baseless-120000926.html
NanoViricides, Inc. Demands Retraction of the Baseless and Inaccurate Libelous Article by an Anonymous Short Seller Posted on SeekingAlpha Website
NanoViricides, Inc.
February 14, 2014 10:06 AM
WEST HAVEN, Conn.--(BUSINESS WIRE)--
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) has demanded from Seeking Alpha the removal of a damaging, baseless and inaccurate article posted by a person who was shorting NNVC common stock.
It is obvious that the anonymous author of this article orchestrated the publication of this article in connection with a massive short position which this person was a major beneficiary of, possibly in collusion with others. The article was clearly designed to manipulate the price of the Company’s common stock downwards for significant personal gains for the persons with short position in the stock including this anonymous author, at the expense of the Company’s shareholders. The article is pure libel, full of numerous false statements, inaccuracies, innuendos, is not based on any factual information about the Company, and twists many facts to fit the person’s motivation to cause a damaging view about the Company. The article has caused significant damage to the Company and its shareholders.
The Company has demanded retraction of the article from the SeekingAlpha website and disclosure of the identity of the anonymous person who posted it. The full text of the demand is posted on our website under the item: “NanoViricides Demands Retraction of the Damaging Article by an Anonymous Short Seller Posted on SeekingAlpha Website”.
The Company is also preparing a complaint to file with the Securities and Exchange Commission to request it to investigate this stock price manipulation.
NanoViricides, Inc. is fully prepared to seek appropriate legal action against parties involved in this libelous attack.
http://finance.yahoo.com/news/nanoviricides-inc-demands-retraction-baseless-120000926.html
NanoViricides, Inc. Demands Retraction of the Baseless and Inaccurate Libelous Article by an Anonymous Short Seller Posted on SeekingAlpha Website
NanoViricides, Inc.
February 14, 2014 10:06 AM
WEST HAVEN, Conn.--(BUSINESS WIRE)--
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) has demanded from Seeking Alpha the removal of a damaging, baseless and inaccurate article posted by a person who was shorting NNVC common stock.
It is obvious that the anonymous author of this article orchestrated the publication of this article in connection with a massive short position which this person was a major beneficiary of, possibly in collusion with others. The article was clearly designed to manipulate the price of the Company’s common stock downwards for significant personal gains for the persons with short position in the stock including this anonymous author, at the expense of the Company’s shareholders. The article is pure libel, full of numerous false statements, inaccuracies, innuendos, is not based on any factual information about the Company, and twists many facts to fit the person’s motivation to cause a damaging view about the Company. The article has caused significant damage to the Company and its shareholders.
The Company has demanded retraction of the article from the SeekingAlpha website and disclosure of the identity of the anonymous person who posted it. The full text of the demand is posted on our website under the item: “NanoViricides Demands Retraction of the Damaging Article by an Anonymous Short Seller Posted on SeekingAlpha Website”.
The Company is also preparing a complaint to file with the Securities and Exchange Commission to request it to investigate this stock price manipulation.
NanoViricides, Inc. is fully prepared to seek appropriate legal action against parties involved in this libelous attack.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
